Holen Sie sich die Stockscreener-App
1.03
3.00%
0.03
Handel nachbörslich:
1.01
-0.02
-1.94%
Schlusskurs vom Vortag:
$1.00
Offen:
$1
24-Stunden-Volumen:
1.07M
Relative Volume:
0.50
Marktkapitalisierung:
$118.81M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.6242
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
+6.85%
1M Leistung:
-32.68%
6M Leistung:
-11.97%
1J Leistung:
-50.24%
1-Tages-Spanne:
$0.9651
$1.045
1-Wochen-Bereich:
$0.96
$1.105
52-Wochen-Spanne:
$0.6611
$3.43
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.03 | 115.35M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Cantor Fitzgerald Issues Positive Outlook for FATE Earnings - MarketBeat
Multi factor analysis applied to Fate Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Tools to monitor Fate Therapeutics Inc. recovery probabilityBuy Signal & Growth Oriented Trade Recommendations - newser.com
Automated trading signals detected on Fate Therapeutics Inc.Short Setup & Accurate Buy Signal Alerts - newser.com
Will Fate Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Is Fate Therapeutics Inc. stock undervalued vs historical averagesEarnings Trend Report & Capital Efficient Trade Techniques - newser.com
Exit strategy if you’re trapped in Fate Therapeutics Inc.Portfolio Return Summary & Daily Entry Point Trade Alerts - newser.com
Will Fate Therapeutics Inc. see short term momentumEarnings Risk Summary & Real-Time Volume Spike Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts - TipRanks
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 Pullback Review & Free Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-16 18:05:52 - newser.com
Will Fate Therapeutics Inc. stock recover faster than market2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities - The Globe and Mail
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks - TipRanks
Why Fate Therapeutics Inc. stock remains a top recommendationPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
How resilient is Fate Therapeutics Inc. stock in market downturns2025 AllTime Highs & Weekly High Return Opportunities - newser.com
Fate Therapeutics (NASDAQ:FATE) Announces Quarterly Earnings Results - MarketBeat
Fate Therapeutics: Q3 Earnings Snapshot - Connecticut Post
Analyzing drawdowns of Fate Therapeutics Inc. with statistical tools2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - newser.com
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating - 富途牛牛
Fate Therapeutics earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Fate Therapeutics Q3 net loss widens - MarketScreener
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - The Manila Times
FATE THERAPEUTICS INC SEC 10-Q Report - TradingView
Why Fate Therapeutics Inc. stock is a value investor pickJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - newser.com
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fate Therapeutics Inc-Aktie (FATE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '25 |
Sale |
1.06 |
14,466 |
15,396 |
334,898 |
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):